← Eichor
Study identifier: NCT06558604 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma

Condition: Lymphoma, Mantle-Cell  ·  Sponsor: The Lymphoma Academic Research Organisation

PhasePhase 2
Planned participants100
Who can joinAll sexes, 18 Years to 79 Years
Healthy volunteersNo

About this study

This open-label, multicenter, three cohorts, phase II study is designed to assess a combination of Zanubrutinib/Venetoclax/Glofitamab or Venetoclax/Glofitamab in high-risk subjects with either first line or R/R Mantle Cell Lymphoma (MCL). Three independent cohorts will be run: * Cohort A will include subjects with a primary refractory or progressive disease within 24 months from initiation of first line treatment (POD 24). * Cohort B will be open for subjects with R/R MCL and refractory or progressive to a BTK inhibitor given previously (\>24 months if first line). * Cohort C will only enrol newly diagnosed and untreated MCL subjects with very high-risk features.

This description comes directly from the study's public registry record.

Talk to the study team

Julie JULIE ASSEMAT  ·  +33 (4) 27 01 27 51  ·  julie.assemat@lysarc.org

Always discuss trial participation with your own doctor first.

Locations (16)

Az Sint-Jan Brugge - Oostende AvBruges, BelgiumRecruiting
Institut Jules BordetBrussels, BelgiumRecruiting
Chu de LiegeLiège, BelgiumRecruiting
Chu Ucl Namur - Site GodinneYvoir, BelgiumRecruiting
Aphp - Hopital Henri MondorCréteil, FranceRecruiting
Chu Dijon BourgogneDijon, FranceRecruiting
Chu de Lille - Hopital Claude HuriezLille, FranceRecruiting
Institut Paoli CalmettesMarseille, FranceRecruiting
Chu de MontpellierMontpellier, FranceRecruiting
Chu de NantesNantes, FranceRecruiting
Chu Lyon-SudPierre-Bénite, FranceRecruiting
Chu de Reims - Hopital Robert DebreReims, FranceRecruiting

+ 4 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06558604